Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma

Abstract

Background Treatments based on the inhibition of pivotal signals of cancer stem cells (CSCs) are on a promising track. Recent studies have shown that targeting CSCs with broader immune‐based therapeutic methods, for example, the anti‐CD47 treatment, may serve as a more potent strategy for eliminating these intractable cells. We aimed to explore the prognostic effects of CD47/CD133 and the potential therapeutic significance of CD47 in esophageal squamous cell carcinoma (ESCC). Methods Immunohistochemistry was employed to identify the characteristics of CD47 and CD133 in 26 pairs of tumor tissues and adjacent non‐tumor tissues and 136 ESCC tissues. Kaplan‐Meier analysis and Cox proportional hazards models were built for estimating the prognostic values of CD47 and CD133 expression and their combined stemness index. Sphere formation assays were undertaken to explore the effects of CD47 inhibition on primary human ESCC CSCs. Results Results conclude that CD47 and CD133 expression is increased in tumor tissues as compared to adjacent non‐tumor tissues. A positive correlation between CD47/CD133 expression and differentiation was found in 136 ESCC patients. Survival analysis indicated that patients with high CD47 or CD133 expression exhibited poor overall survival and progression‐free survival (PFS). The combination of high CD47 and CD133 expression was a reliable independent prognostic factor for both OS (HR = 1.940, 95% CI = 1.399‐2.690, P < 0.0001) and progression‐free survival (HR = 1.883, 95% CI = 1.384‐2.562, P < 0.0001). Notably, CD47+ CD133+ ESCC cells were observed to possess the characteristics of CSCs, and anti‐CD47 treatment veritably eliminated the CSCs pool. Conclusions The stemness index determined by the expression of CD47 and CD133 is a promising prognostic predictor, and CD47 is a potential therapeutic target for CSCs in ESCC patients.

Transcriptome-based Stemness Indices Analysis Reveals Platinum-based Chemotheraputic Response Indicators in Advanced-stage Serous Ovarian Cancer

“…In the PFS curves of mRNAsi/corrected mRNAsi, we observed a tendency without statistical signi cance that within approximately 4 years, the PFS rate of high mRNAsi/corrected mRNAsi group was higher than that of low mRNAsi/corrected mRNAsi group. This was very different from our understanding that greater stemness of cancer cells would eventually lead to a shorter PFS [11,12]. The results might be explained by three possible causes.…”

“…Similar results were observed in the analysis of corrected mRNAsi. This nding was very different from our understanding that greater stemness of tumor cells would indicate decreased progression-free survival [11,12]. The above results indicated that the mRNAsi score in SOC samples had a close correlation with the histopathological grades.…”

Immunomodulatory Molecules On Lung Cancer Stem Cells From Lymph Nodes Aspirates

“…One explanation might be that MTCs lose expression of some molecules during differentiation. The knockdown of CD47 suppressed certain stem-like properties of cancer cells, such as self-renewal and chemoresistance, suggesting that targeting CD47 could not only activate the phagocytosis of macrophages but also could be used to enhance treatment against CSCs [29]. Hence, CD47 expression may be another mechanism used by lung cancer cells, especially lung CSCs, to escape phagocytosis.…”

Korelasi Ekspresi CD47 terhadap Faktor-Faktor Klinikopatologi pada Karsinoma Ovarium

“…Yuan J membagi usia menjadi <50 tahun dan >50 tahun dengan nilai p=0,34 namun penelitian dilakukan pada kasus kanker payudara dengan triple negative. 29,31,32 Data pada penelitian ini tidak sejalan dengan Aktas S dkk dan Baccelli I dkk. Aktas S dkk mendapatkan bahwa ekspresi CD47 meningkat seiring usia dengan nilai p yang signifikan (p=0,018), hasil yang berbeda dikarenakan menggunakan uji Chi square dan Mann whitney selain jumlah pasien lebih banyak, serta dilakukan pada kasus neuroblastoma.…”